Early research (Phase 1)Looking for participantsNCT07224776
What this trial is testing
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Who this might be right for
Proteinuric Renal DiseaseProteinuric Kidney DiseaseProteinuria+1 more
Brigham and Women's Hospital 20